VTP 43742

Drug Profile

VTP 43742

Alternative Names: VTP43742

Latest Information Update: 11 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Allergan
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psoriasis
  • Phase I Autoimmune disorders
  • Preclinical Multiple sclerosis

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 14 Sep 2016 Allergan enters into a definitive merger agreement with Vitae Pharmaceuticals
  • 16 Mar 2016 Positive top-line efficacy, pharmacodynamics and adverse events data from a phase IIa trial in Psoriasis released by Vitae Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top